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ABSTRACT
Hyperadrenocorticism (HAC) is one of the most common endocrine disorders in dogs, and establishing 
a diagnosis requires extensive diagnostics. In this study, 54 dogs with spontaneous hyperadrenocorticism were 
included, and were divided in two groups: the treated group which consisted of 35 dogs (trilostane therapy 
32, adrenalectomy 3) and the non-treated group, which consisted of 19 dogs. According to the Kaplan-Meyer 
survival curve, the mean survival time of the whole population was 29.6 months, where the untreated patients’ 
mean survival time was 12.7 months, and in patients with therapeutic intervention it was 34.7 months. In 
the multivariable Cox proportional hazards model, no single clinical or laboratory parameter was found to 
signiﬁ cantly inﬂ uence the outcome. The signiﬁ cance of this research is in its contribution to understanding the 
natural course of spontaneous canine hyperadrenocorticism. 
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Introduction 
Hyperadrenocorticism (HAC), or Cushing’s syndrome, is one of the most common 
endocrine disorders in dogs, and is characterized by chronically increased circulating 
cortisol concentration, which causes both physical and biochemical changes (KOOISTRA 
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and GALAC, 2012). Clinical presentation consists of an almost pathognomonic constellation 
of clinical signs (polyuria/polydipsia, polyphagia, muscle wasting, “potbelly”, thinning 
of the skin and bilaterally symmetrical alopecia), but the more subtle cases of Cushing’s 
syndrome can be difﬁ cult to diagnose, and the interpretation of dynamic adrenal function 
tests is complicated when other diseases are present (GILOR and GRAVES, 2011). HAC 
has an insidious onset and is slowly progressive over many months or even years. Most 
owners consider the early signs as part of the normal aging process of their dog. In a few 
cases, clinical signs may be intermittent, with periods of remission and relapse, whereas 
in others there may be an apparent rapid onset and progression of clinical signs. Thus, 
making a diagnosis requires considerable clinical insight (KOOISTRA and GALAC, 2012; 
PETERSON, 2007).
The syndrome can be caused by oversecretion of the adrenocorticotropic hormone 
(ACTH) from a pituitary abnormality (pituitary-dependent HAC or PDH), the result 
of a primary adrenocortical tumour (adrenal-dependent HAC or ADH) or iatrogenic 
administration of glucocorticoids (HERRTAGE and RAMSEY, 2012). A presumptive 
diagnosis of HAC can be made from clinical signs, physical examination, routine 
laboratory tests, and diagnostic imaging ﬁ ndings, but the diagnosis must be conﬁ rmed by 
hormonal assay (BEHREND et al., 2013). Regardless of which test is used, a high degree of 
clinical suspicion is mandatory to avoid false-positive test results (BEHREND et al., 2013; 
KOOISTRA and GALAC, 2012; PETERSON, 2007).
Ultrasonography has been determined to be a useful primary screening modality to 
identify abnormal adrenal glands (CHOI et al., 2011; GROOTERS et al., 1994; GROOTERS 
et al., 1996) and testing for HAC is recommended after identiﬁ cation of bilateral 
adrenomegaly or unexpected identiﬁ cation of an adrenal mass on imaging performed for 
another problem (BEHREND et al., 2013). 
Treatment of HAC depends on whether it is PDH or ADH. At the level of the pituitary 
gland PDH can be treated surgically with transsphenoidal hypophysectomy (VAN RIJN et 
al., 2015) in which, when the surgeon has acquired the necessary experience, the results 
compare favourably with those of chemotherapy using mitotane. This procedure can 
only be performed in specialized institutions. To date several attempts have been made 
to medically reduce pituitary hypersecretion of ACTH, and these investigations have 
reported clinical improvement but have not been followed by broader use (GALAC et 
al., 2010). In everyday practice, medical treatment is aimed at the adrenal level to reduce 
the glucocorticoid excess, either medically or surgically. The two most commonly used 
medications are mitotane and trilostane (HELM et al., 2011). Treatment with trilostane has 
become the medical treatment of choice (PEREZ ALENZA et al., 2006; GALAC et al., 2009). 
For ADH in cases of resectable adrenal tumours, adrenalectomy is the recommended 
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treatment, but in cases of non-resectable tumours, medical treatment with trilostane is the 
treatment of choice (ARENAS et al., 2014). 
Since HAC presents a signiﬁ cant endocrinopathy in dogs, and treatment regimes 
have changed over time, as well as prognosis of the disease, the aim of the present study 
was to determine the clinical and laboratory ﬁ ndings present in spontaneous canine HAC, 
compare them to outcome, and evaluate epidemiologic, clinical and laboratory ﬁ ndings 
that could be associated with survival time. In addition, we hypothesized that treated 
dogs (with trilostane or adrenalectomy) would have signiﬁ cantly longer survival time 
compared to dogs for which no treatment was instituted. Furthermore, to the authors’ 
knowledge there were no previously published studies dealing with hyperadrenocorticism 
in Croatia. Therefore we wanted to compare results obtained from our population with the 
results of other studies.
Materials and methods
Clinical cases. All the dogs diagnosed with spontaneous HAC at the Clinic for 
Internal Diseases of the Veterinary Faculty in Zagreb, between August 2009 and August 
2014, were included in this study. Before analysing the data, we assigned the patients 
to two groups: the non- treatment and the treatment group. The decision not to treat the 
dogs was made by their owners predominantly due to ﬁ nancial reasons. The following 
data were analysed: epidemiological [breed, sex, weight, size of the dog according to 
body weight (<10 kg, and >10 kg), age at diagnosis (< 10 years, and >10 years)], selected 
clinical signs (polyuria/polydipsia, polyphagia, abdominal distention, liver enlargement, 
muscle weakness, lethargy, panting, billateraly symmetrical alopecia, calcinosis cutis, 
gonadal atrophy, neurological signs and hypertension), concomitant diseases (diabetes 
mellitus, urinary tract infection), results of abdominal ultrasound examination, and 
from routine blood analysis selected haematological (haematocrit, thrombocytes and 
white blood cell count) and biochemical parameters: alkaline phosphatase, alanine 
aminotransferase, aspartat aminotransferase, glucose, urea, creatinine, cholesterol and 
triglycerides). Bacteriological examination of the urine was performed at the time of 
diagnosis. In patients that were hospitalised, cystocentesis was performed, and in patients 
that were treated as outpatients, a spontaneous voided sample was collected. For voided 
samples quantitative as well as qualitative bacteriological examination was performed. 
For all cases concurrent diseases, at presentation or during study as detected by clinical 
examination, complete blood count, biochemistry proﬁ les, and imaging modalities were 
recorded. Additionally, blood pressure measurements were performed at the time of 
diagnosis using the Doppler oscillometric system. Hypertension was deﬁ ned as a systolic 
blood pressure >160 mm Hg (BROWN et al., 2007). 
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Diagnostic procedures. The presumptive diagnosis of HAC was made on the basis 
of clinical history, physical examination, ultrasonography ﬁ ndings, and the results of 
haematology, serum biochemistry and urinalysis ﬁ ndings. The diagnosis of HAC was 
conﬁ rmed, either by a combination of two adrenal function tests [in which case one had to 
be low-dose dexamethasone suppression test (LDDST)] or at least one positive endocrine 
test (ACTH stimulation test or LDDST) combined with the positive ultrasonography 
ﬁ ndings. Results of the ACTH stimulation test were considered positive when post-
ACTH cortisol concentration was > 600 nmol/l, and LDDST results were considered 
positive if at 8 hours following suppression there was no suppression to below 40 nmol/l 
(HERRTAGE, 2004). Individually performed diagnostics are showed in Table 1. 
Table 1. Combinations of diagnostic methods applied in establishing a diagnosis of spontaneous 
HAC in researched population (n = 54). 
Diagnostic test Number of patients
US + LDDST 8
US + ACTH stimulation test 34
US + UCCR 1
LDDST + ACTH stimulation test 11
Total 54
Endocrinologic tests were considered to be positive according to values proposed by HERRTAGE (2004). 
US - ultrasound examination, LDDST - low dose dexamethasone supression test, ACTH stimulation test - 
adrenocorticotropic hormone stimulation test, UCCR - urine cortisol creatinine ratio.
Adrenal function tests. For the ACTH stimulation test, plasma cortisol concentrations 
were measured before and 1 hour after i/v injection of 250 μg tetracosactrin (Synacthen, 
Novartis). LDDST consisted of measurements of cortisol concentrations before and 4 
and 8 hours after administration of 0.01mg/kg dexamethasone (Dexamethasone, Alfasan 
International). For UCCR two consecutive urine samples were collected in which 
creatinine and cortisol concentrations were measured (Synlab, Germany, Augsburg). 
Cortisol was measured by external commercial laboratories by radioimmunoassay or 
immunoradiometric assay validated for use in dogs, with appropriate quality controls.
Diagnostic imaging. Forty-two patients were examined by ultrasonography (MyLabTM 
40, Esaote) with a 5-8 MHz curved array transducer, to determine the size of the adrenal 
glands. For the diagnosis of HAC both glands had to be of normal shape, echogenicity 
and of symmetrical size, with less than 5 mm difference in thickness between glands. 
Measurements were made on the caudal pole of the adrenal glands, and for dogs weighing 
> 10 kg the cut-off value was set at 7.4 mm (BARBERET et al., 2010; PEY et al., 2012), and 
for dogs weighing < 10 kg the cut-off value was 6.4 mm (CHOI et al., 2011). For diagnosis 
of ADH, a large solitary and abnormally shaped adrenal mass, with or without invading 
adjacent structures and with a difference of more than 5 mm between adrenal gland 
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measurement values, had to be established. The presence of thrombi and intraabdominal 
metastases to adjacent organs (e.g. lymph nodes, kidney and or liver) were recorded. 
Tumour staging was based on the ﬁ ndings of abdominal ultrasonography and thoracic 
radiography. 
Trilostane therapy. Thirty-two dogs were included in the trilostane (Vetoryl, Dechra) 
treatment group. The initial dose was between 2 and 3 mg/kg PO q 24 h, and was adjusted 
according to the clinical status and the results of the ACTH stimulation test. 
Dogs treated with trilostane were reviewed one week after the start of treatment, 
and at the 1st, 3rd, and 6th month after treatment, and then every 6-12 months thereafter. 
At each evaluation, history, physical examination, complete blood work and urinalysis 
and an ACTH stimulation test or UCCR were performed. ACTH stimulation tests were 
performed between 2 and 6 hours post pill in dogs in which the treatment regimen was 
once daily, and in those receiving therapy twice daily, at the time of administration of 
morning dose. 
Adrenalectomy. Three dogs with ADH underwent adrenalectomy. During induction 
of general anaesthesia all the dogs received a single injection of cefazolin sodium (22 mg/
kg i/v) as antimicrobial prophylaxis. The dogs were also treated with dexamethasone (1 
mg/kg i/v) prior to anaesthesia, and continued to receive glucocorticoids parenterally until 
they started to eat. In all dogs anaesthesia was induced with slow i/v injections of fentanyl 
(2 μg/kg i/v) and propofol (4 mg/kg i/v) via an i/v catheter, followed by maintenance 
with isoﬂ urane in oxygen after endotracheal intubation (MASSARI et al., 2011). Midline 
laparotomy was performed and the adrenal glands were removed via gentle dissection. 
Haemostasis was achieved via manual vessel ligation or bipolar electrocautery, or a blood 
vessel sealing device (Ligasure, Covidien, USA). If the tumour had invaded the kidney 
or a thrombus had obstructed the renal vein, concurrent nephrectomy was performed 
(1 dog). After surgery, as standard care all the dogs were given i/v crystalloid ﬂ uids, 
cefazolin (22 mg/kg i/v) and analgesic drugs (fentanyl 2-3 μg/kg/h i/v) progressively 
tapered and discontinued when the dogs no longer had signs of abdominal pain on gentle 
abdominal palpation. Administration of prednisolon (1 mg/kg PO, q24h) was started after 
the dog began to eat and drink, which was between 24-48 hours post operation. 
Histopathology was performed on samples obtained by laparotomy and they were 
classiﬁ ed as either benign (adenoma) or malignant (carcinoma) according to vascular 
invasion, the presence of high mitotic rate, increased nuclear pleomorphism, a high 
percentage of tumour necrosis or some combination of these ﬁ ndings (LABELLE et al., 2005). 
Statistical analyses. For the descriptive analyses of continuous data, the mean, 
standard deviation, and the range of values are reported. For categorical data, frequencies 
and percentages are given. The population characteristics of both groups were compared 
using the chi-square test for sex, breed, concurrent illness and clinical signs. Survival 
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time analysis was performed using a Kaplan-Meier survival curve, with the dogs still 
alive at the end of the study being censored. The log-rank test was used to compare 
survival curves of the 2 groups. Overall survival was deﬁ ned as the time from establishing 
the diagnosis, or from the beginning of treatment, to the day of death. Univariate Cox 
proportional hazard regression analysis was performed to screen potential predictor 
factors for subsequent inclusion in a multivariate model. Potential predictive variables 
including: epidemiologic factors (age, sex, breed, breed size, reproductive status and 
weight), clinical signs detected at diagnosis (polyuria/polydipsia, polyphagia, abdominal 
distention, liver enlargement, weakness, lethargy, panting, dermatologic signs, concurrent 
diseases, neurologic signs and blood pressure) laboratory ﬁ ndings, and the presence of 
therapy were analysed. 
To identify the independent impact of variables on the survival time of the dogs, 
multivariate analysis was performed. The variables tested for their impact on overall 
survival were those signiﬁ cantly correlated at the univariate level. Hazard ratios (HR) 
with a 95 % conﬁ dence interval (CI) were calculated. For all the statistical analyses P ≤ 
0.05 was considered signiﬁ cant. 
Results
Fifty-four dogs were included in this study. There were 30 female dogs (12 intact and 
18 spayed) and 24 male dogs (18 intact and 6 neutered). There were 22 breeds represented 
in this investigation and their distribution is presented in Table 2. PDH was diagnosed in 
41 (75.9 %) dogs, and ADH in 13 dogs (24.1 %).












Italian Water Dog 2
Alaskan Malamute, American Staffordshire Terrier, Beagle, Bernese Mountain 
dog, Bichon Frisee, Croatian Shepherd Dog, Dalmatian, English Cocker Spaniel, 
German Shepherd Dog, German Short-haired Pointer, Golden Retriever, Irish 
Setter, Scottish Terrier 
1 of each 
(total 13)
Total 54
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The mean age at the time of diagnosis was 10 years. The mean age at admission in the 
group of treated dogs was 10.2 years, and for those in group of non-treated dogs was 9.8 
years. Mean body weight was 21.6 kg, ranging from 2.7 to 46 kg, and for treated dogs it 
was 21.8 kg in a range from 5 kg to 44.4 kg, and for those in non-treated group 21.2 kg, 
ranging from 2.7 kg to 46 kg. Of epidemiologic factors only breed size was found to be 
statistically signiﬁ cant (log rank P = 0.034).
Table 3. Categorical clinical values of investigated population (n = 54), treatment group (n = 35), 






Log rank P 
value
Polyuria/polydipsia 44 (81 %) 31 (89 %) 13 (68 %) 0.070
Polyphagia 23 (43 %) 17 (49 %) 6 (32 %) 0.619
Abdominal distention 33 (61 %) 22 (63 %) 11 (58 %) 0.571
Liver enlargement 36 (67 %) 26 (74 %) 10 (53 %) 0.754
Muscle weakness 28 (52 %) 18 (51 %) 10 (53 %) 0.112
Lethargy 15 (28 %) 10 (29 %) 5 (26 %) 0.373
Panting 38 (70 %) 24 (69 %) 14 (74 %) 0.491
Billateraly symmetrical alopecia 26 (48 %) 18 (51 %) 8 (42 %) 0.873
Calcinosis cutis 4 (7 %) 2 (6 %) 2 (11 %) 0.167
Gonadal atrophy 18/30 (60 %) 13/18 (72 %) 5/12 (42 %) 0.749
Neurological signs 5 (9 %) 4 (11 %) 1 (5 %) 0.039
Hypertension 42 (76 %) 28 (80 %) 14 (74 %) 0.113
Urinary tract infections 28 (52 %) 17 (49 %) 11 (58 %) 0.435


































Gonadal atrophy was considered to be present in bitches with cycle irregularities and in males having soft 
and spongy testicles on physical examination. EPI - Exocrine pancreatic insufﬁ ciency, HCM - Hypertrophic 
cardiomyopathy.
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The results of clinical categorical data are presented in Table 3. The most frequently 
encountered clinical sign was polydipsia and polyuria, followed by panting and  by 
abdominal distension and liver enlargement. With decreasing frequency, polyphagia, 
weakness, lethargy and dermatological signs were observed. The only statistically 
signiﬁ cant difference was the presence of neurological signs (log rank P = 0.039). 
The most commonly encountered concurrent disease was diabetes mellitus, which 
was present in 7 patients (13 %), of those 6 (17 %) were in the treatment, and one in 
the non-treatment group (5 %). All the patients with diabetes mellitus were treated with 
recombinant human NPH insulin twice daily and controlled with serial glucose curves, 
according to NELSON (2010). The presence of concurrent diseases was not found to be 
statistically signiﬁ cant (log rank P = 0.084). 
Selected standard laboratory parameters are presented in Table 4. Most of the patients 
had some combination of changed laboratory parameters that often accompany HAC, 
such as lymphopenia, eozinopenia, thrombocytosis and increased values of alkaline 
phosphatase, glucose, cholesterol and triglycerides. However, only the presence of 
thrombocytosis was found to be statistically signiﬁ cant (log rank P = 0.014). 
There were 42 dogs (76 %) with hypertension in this study and their mean systolic 
arterial pressure (mSAP) was 219.19 ± 29.55 mm Hg, range 164-270 mm Hg. Of those 28 
(80 %) were in the treatment group (range: 164 - 270 mm Hg, mSAP 209.50 ± 31.49 mm 
Hg), and 14 (74 %) in the non-treatment group (range: 172 - 264 mm Hg, mSAP 223.14 ± 
31.49 mm Hg). All the dogs in the treatment group and 6 dogs in the non-treatment group 
were treated with either enalapril or amlodipine, or with a combination of these according 
to CARR (2010).
An adverse reaction to the medical therapy were observed in 8 (22.8 %) patients 
who had one or more episodes of weakness, loss of appetite, vomiting or diarrhoea at 
different times throughout the study. Most patients responded well to administration of 
i/v ﬂ uids and discontinuation of the medication. In 3/8 patients, electrolyte disturbance 
was recorded and glucocorticoids were administered for a short term. No patient needed 
permanent discontinuation of the therapy or long-term glucocorticoid treatment, however 
2 patients were euthanized after repeated episodes of adverse reactions.
Thirteen dogs presented with a unilateral adrenal mass (24.1 %), of which 6 were 
on the left (6/13, 46 %), and 7 (7/13, 54 %) on the right side. The maximal dorsoventral 
thickness ranged from 12 to 49 mm (mean 28.83 ± 13.02 mm), in all patients there was 
a difference of > 5 mm between the affected and the contralateral gland. Thrombi were 
recorded in 6/13 (46 %). Three dogs underwent adrenalectomy, and in one nephrectomy 
was performed. Histopathology results were available in all 3 dogs treated surgically. One 
dog had adrenocortical adenoma, and the remaining two had carcinomas. 
85Vet. arhiv 86 (1), 77-94, 2016








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































86 Vet. arhiv 86 (1), 77-94, 2016
I. Kiš et al.: Spontaneous hyperadrenocorticism in dogs
At the date of censorship 28 dogs were still alive. The remaining 26 dogs had died 
or were euthanized for the following reasons: status epileptics (n = 2) and appearance 
of seizures or cluster seizures (n = 2), diabetic ketoacidosis (n = 1), mammary gland 
carcinoma (n = 2), liver tumour (n = 1), progression of mitral insufﬁ ciency (n = 2) 
and dilatative cardiomiopathy (n = 1), renal insufﬁ ciency (n = 1), pneumonia (n = 2) 
gastrointestinal infection (n = 2), urinary tract infection (n = 1), weakness and anorexia (n 
= 4). For ﬁ ve dogs the cause of death was unknown (n = 5). In only 5 patients necropsy 
was performed which conﬁ rmed clinical suspicions (pituitary adenoma, liver tumour, 
mammary gland carcinoma, pneumonia and gastrointestinal infection). 
Kaplan-Meier survival estimates. The mean survival time for the investigated 
population was 29.6 months (SE: 2.5; 95 % CI: 24.7-34.5 months). There was a signiﬁ cant 
difference between the survival time (Fig. 1) of treated dogs (mean 34.7; SE: 4.4; 95 % 
CI: 26.1-43.3 months) and untreated dogs (mean 12.7; SE: 3.3; 95 % CI: 6.2-19.1 months) 
(P = 0,014). At the end of the study there were 14 (40.0 %) and 12 (63.1 %) dead dogs in 
the treated and untreated groups, respectively (P < 0.05). The 1 year survival fraction for 
dogs without therapy was 33 ± 12 %, whereas for dogs with therapy it was 62 ± 9 % (P 
= 0.027). When comparing dogs without therapy to dogs under therapy, dogs that were 
not treated had 2.43 times (95 % CI: 1.01-5.83) higher chance of death compared to the 
treated dogs. 
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Additionally, survival time was investigated separately for PDH and ADH, as these 
are two different forms of naturally occurring HAC. Of 41 dogs diagnosed with PDH (Fig 
2), 30 were in the treatment group, and at the time of control there were 17 alive and 13 
dead dogs. In the non-treatment PDH group there were 5 dogs alive and 6 dead. The mean 
survival time for dogs with PDH was 31.4 months (SE: 2.9; 95 % CI: 25.7-37.1 months). 
The mean survival time for treatment dogs with PDH was 33.9 months (SE: 4.7; 95 % 
CI: 24.7-43 months) and for the non-treatment group it was 15.5 months (SE: 4.6; 95 % 
CI: 6.6-24.4) but there was no statistically signiﬁ cant difference between the treatment 
and non-treatment groups (P = 0.152). Of 13 dogs diagnosed with ADH, three underwent 
adrenalectomy and were alive at the time of writing this manuscript. Of the remaining 10 
dogs, two were in the treatment group of which 1 was alive and 1 dead, and the remaining 
8 were in the non-treatment group and for them the survival curve is presented in Fig 3. 
The mean survival time for dogs with ADH and without treatment was 6.1 months (SE: 
1.96; 95 % CI: 2.2-9.9). At the time of censorship in the non-treatment group of dogs with 
ADH there were 6 dogs dead and 2 alive. 
Fig. 2. Kaplan-Meier survival curve for dogs diagnosed with PDH (n = 41), both treated (n = 30) 
and non-treated (n = 11) dogs
Epidemiologic, clinical and laboratory variables at time of diagnosis, as well as the 
presence of therapy were examined for their potential inﬂ uence on survival time (Table 5). 
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therapy positively correlated, with survival. In the multivariable model, only the presence 
of therapy positively correlated with outcome.
Fig. 3. Kaplan-Meier survival curve for non-treated dogs with ADH (n = 8)
Table 5. Results of Cox univariate and multivariate regression for the investigated population (n = 54)
Variable b SE P Exp (b) 95 % CI of Exp (b)
Univariate
Dog size (>10 kg) 0.89 0.45 0.047 2.43 1.02-5.84
Therapy - 0.93 0.41 0.022 0.39 0.18-0.87
Multivariate
Therapy - 0.93 0.41 0.022 0.39 0.18-0.87
Discussion
In this study, the long-term survival time, with and without treatment, were evaluated 
for dogs with spontaneous HAC. Although PDH is the most common form of HAC 
(FELDMAN and KASS, 2012; ARENAS et al., 2014) and accounts for approximately 85 % 
of all cases, in this study it was diagnosed in 75.9 % (41/54) of all patients, which is 
compatible with the overall weight of the dogs (21.6 kg), suggesting that this population 
is not a classical small breed population affected by HAC, which is also in accordance 
with the breeds represented in this study. The reason for this difference might be that the 
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ﬁ rst opinion practices, but also our investigated population may be truely representative 
of naturally occurring HAC in Croatia. 
In our study we compared the patients in which we employed one of two recommended 
treatment options (trilostane for PDH and non-resectable ADH and adrenalectomy for 
resectable ADH), with untreated dogs. The motive for this investigation was the relatively 
high price of both treatment options, which was unacceptable for some owners, and the 
simultaneous lack of studies in which adequate diagnostic procedures were carried out, 
but no treatment was instituted. The results of this study suggest that there is signiﬁ cant 
difference in survival time when treatment is affordable. These ﬁ ndings provide 
information important for clinicians presented with cases of spontaneous HAC, and they 
may now give objective information to owners regarding the beneﬁ ts of the therapy. 
Of the two most commonly available medical treatment options, mitotane and 
trilostane, for both ADH (HELM et al., 2011) and PDH (ARENAS et al., 2014), in our study 
all the dogs that were medically treated were treated with trilostane, predominantly due 
to its availability. For dogs with PDH treated with trilostane the mean survival time in 
the research by NEIGER et al. (2002) was 18.3 months and in the study by BARKER et al. 
(2005) the median survival time was 22 months, which is shorter than in our study (33.9 
months). It is important to notice that the ﬁ rst study had a shorter duration compared to 
the second and to our study, but in the ﬁ rst study, which lasted, three years, there was 
a high percentage of surviving patients (65.4 %) censored at the end of the research, 
and therefore this did not affect the Kaplan-Meier survival curve. In our study, due to 
the small number of patients with PDH, there was no statistically signiﬁ cant difference 
between treated and those that were not treated even though there was large difference 
in survival time. The mean survival time of patients with PDH and without therapy (15.5 
months) was much longer than for patients with ADH and without therapy (6.1 months), 
which corresponds to the differences between pituitary and adrenal tumours (GALAC et 
al., 2010).
Even though therapy with trilostane is considered to be associated with less 
worrisome adverse effects, complications of the therapy have been reported and have 
included anorexia, vomiting, diarrhoea, weakness, shivering (PEREZ ALENZA et al., 
2006) or unusual listlessness (FELDMAN, 2011). In our study, there were 22.8 % adverse 
reactions present, which is less than in the investigation by PEREZ ALENZA et al. (2006), 
in which 25 % similar adverse reactions were observed. FELDMAN (2011) reports that in 
the review of eight studies on 191 dogs treated once daily with trilostane, 22 % of patients 
were sufﬁ ciently ill to have the adverse effects reported, which is in agreement with our 
results.
In our investigated population, comorbidites were the cause of euthanasia or death 
in 7 patients, in which no direct correlation with HAC could be established. However, 
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all the dogs that succumbed to inﬂ ammatory processes, as well as the dog with diabetic 
ketoacidosis, were in the non-treatment group where it could be presumed that HAC had 
some contributory role. Furthermore, all the patients that had neurological signs present 
at presentation, or where they emerged during therapy, were diagnosed with PDH. For 
those dogs it was presumed that there had been growth of a pituitary adenoma, which was 
conﬁ rmed in one case where necropsy was allowed. For dogs presenting with weakness 
and loss of appetite (n = 4), therapy complications were suspected. Two of those were 
euthanized without further diagnostics, and in two, clinical ﬁ ndings and electrolyte 
abnormalities indicated therapy complications but the owners declined hospitalisation 
and the patients were euthanized. 
There is only a limited number of studies in veterinary medicine that have tried to 
evaluate prognostic factors for dogs with ADH (HELM et al., 2011; ARENAS et al., 2014) 
and PDH (NEIGER et al., 2002; BARKER et al., 2005). In the work by NEIGER et al. (2002) 
no statistically signiﬁ cant inﬂ uence on survival time was found after testing age, weight, 
initial dose of therapy and post-ACTH cortisol concentration. Conversely in the work by 
BARKER et al. (2005), age and weight at diagnosis were signiﬁ cantly negatively associated 
with survival. Age and post-adrenocorticotropic cortisol concentrations, together with 
weakness at presentation, were found to be statistically signiﬁ cant in the work by ARENAS 
et al. (2014), while in the study of HELM et al. (2011) the only prognostically signiﬁ cant 
factor was the presence of metastatic disease. Of potential prognostic factors in our study 
only dog size, the presence of neurological signs and thrombocytosis were found to be 
signiﬁ cant in log rank analysis. However, in the Cox regression model no clinical or 
laboratory parameters were found to signiﬁ cantly inﬂ uence the outcome. The lack of a 
few statistically signiﬁ cant predictive factors might be explained by the endocrine nature 
of the disease with cortisol effects inﬂ uencing all body systems, in which the clinical 
picture is the summation of all the effects of the circulating cortisol (ARENAS et al., 2014). 
Adrenalectomy reportedly has an overall high complication rate, ranging to as 
high as 51 % (SCHWARTZ et al., 2008), with the most common complications including 
postoperative adrenal gland insufﬁ ciency, pulmonary thromboembolism, pancreatitis 
and acute renal failure (KYLES et al., 2003; SCHWARTZ et al., 2008). However, patients 
surviving to discharge achieve a good long-term outcome, with a median survival time of 
more than 10 months (MASSARI et al., 2011). In this study, all three dogs that underwent 
adrenalectomy were alive at the time of writing this paper.
It may be concluded that the ﬁ ndings of this study have proven that the current 
recommended treatment signiﬁ cantly prolongs the life expectation of patients with HAC. 
To the best of the authors’ knowledge there is no study evaluating the long-term outcome 
of HAC patients without therapy.
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One limitation of this study was the lack of control appointments for non-treatment 
group patients dedicated to clinical and endocrinological evaluation, which would enable 
us to better understand the progression of clinical signs in the natural course of the disease. 
For the treatment group, a wide range of ACTH-stimulation tests was used initially in the 
study ranging from 2 to 6 hours post pill, which could have led to decisions about therapy 
change in some patients when the time of maximal effect of trilostane had been missed 
(GALAC et al., 2009).
The other limitation is that the present research included mostly middle-aged or 
old patients, in which there is an increased chance of concurrent diseases. Although 
we excluded all patients with spontaneous HAC euthanized due to concurrent illness, 
it is possible that in some cases concurrent diseases inﬂ uenced the outcome. Still, it is 
reasonable to expect that in every population of spontaneous HAC we would investigate 
a certain proportion of cases with concurrent diseases.
Finally, in veterinary medicine, the recommended treatment modalities prolonged 
the life of our patients in comparison to the natural course of the disease. Additional 
large clinical studies are required to better evaluate the clinical signs and possibly 
ﬁ nd new parameters that could be used as prognostic factors for naturally occurring 
hyperadrenocorticism. 
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SAŽETAK 
Hiperadrenokorticizam jedna je od najčešćih endokrinoloških bolesti koja zahtijeva opsežnu dijagnostiku 
za postavljanje konačne dijagnoze. U ovo su istraživanje bila uključena 54 psa različitih pasmina koji su bili 
podijeljeni u dvije skupine: liječeni pacijenti (trilostan 32 i adrenalektomija 3) u kojoj se nalazilo 35 pasa 
i skupinu bez terapije, u kojoj se nalazilo 19 pasa. Prosječno vrijeme preživljavanja prema Kaplan-Meyer 
krivulji bilo je 29,6 mjeseci, pri čemu je pacijentima iz netretirane skupine aritmetička sredina bila 12,7 
mjeseci, a u pacijenata u kojih se terapijski interveniralo 34,7 mjeseci. Multivarijantnom Cox regresijskom 
analizom nije ustanovljen niti jedan klinički ili laboratorijski pokazatelj koji bi značajno utjecao na ishod 
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bolesti. Doprinos je ovog istraživanja u postizanju boljeg uvida u prirodni tijek bolesti pacijenata sa spontanim 
hiperadrenokorticizmom. 
Ključne riječi: pas, nadbubrežna žlijezda, dijagnostički postupci, ishod________________________________________________________________________________________
